ACR to Provide Image Coordination for National COVID-19 Observational Study (CORAL)

The American College of Radiology® (ACR®) Center for Research and Innovation™ (CRI) will serve as the imaging coordination center for the multicenter COVID-19 Observational Study (CORAL) led by Dr. Catherine “Terri” L. Hough of the Oregon Health & Science University. The CORAL Study is part of the Prevention & Early Treatment of Acute Lung Injury (PETAL) Network, a consortium of academic and affiliated hospitals across the United States – funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health – to conduct clinical trials in patients with or at risk for critical illness, including acute respiratory distress syndrome.

The purpose of CORAL is to inform epidemiology and resource utilization through three interrelated approaches: a registry; a detailed cohort, including a bio-specimen collection correlated with clinical phenotyping and outcomes; and a health system assessment. In collaboration with CORAL leadership, and following standards developed for this study, the ACR CRI will collect imaging exams on registry subjects, create a link between the images and clinical data collected by PETAL, archive images throughout study duration and, once complete, make images accessible to researchers.

At present, little is known about the epidemiology of novel coronavirus (COVID-19) in the United States. Rapid expansion of cases across this country and others necessitates urgent study of severe acute COVID-19 in order to care for patients, inform and develop treatments, target therapeutics, prognosticate and understand health system impacts. The CORAL Study is a responsive effort to these needs.

“We at the ACR are pleased and proud to be part of the effort by our colleagues who are caring for patients suffering with COVID-19 who require hospital care. We hope the collection of imaging and clinical data that the PETAL project creates will lead to improved treatment and diagnosis of COVID-19 complications, including advanced lung disease, stroke and cardiac dysfunction,” says Etta Pisano, MD, chief research officer of the ACR.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”